![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.biopharmadive.com/news/johnson-johnson-numab-yellow-jersey-bispecific-atopic-dermatitis-eczema/717179/
https://www.globenewswire.com/news-release/2024/05/28/2888935/0/en/Numab-Therapeutics-Announces-Johnson-Johnson-to-Acquire-its-Wholly-Owned-Subsidiary-Yellow-Jersey-Therapeutics-Including-Rights-to-NM26-a-Bi-Specific-Antibody-for-the-Treatment-of-.html
https://www.globenewswire.com//news-release/2024/02/14/2828818/0/en/Numab-Therapeutics-and-Ono-Pharmaceutical-Announce-an-Option-and-Collaboration-Agreement-to-Develop-Multi-specific-Antibody-NM49-for-Treatment-of-Cancer.html
https://www.clinicaltrialsarena.com/news/numab-antibody-therapeutic-ad/
https://www.fiercebiotech.com/biotech/numab-raises-111m-to-challenge-genmab-biontech-for-emerging-pd-l1-opportunity